|
|
|
Pharmaceutical Manufacturing and Packing Sourcer
|
Introduction
Recent advances in combinatorial chemistry techniques employed in the pharmaceutical industry have dramatically increased the number of new compounds for evaluation as drug candidates. Approximately half these new chemical entities contain hydrophobic substituents that result in the compounds exhibiting poor aqueous solubility. This lipophilic attribute offers the capability in tailoring the formulation of a new chemical entity into a lipid emulsion drug delivery system to accommodate the specific requirements of the disease with respect to stability, toxicity and efficacy in parenteral administration.
Types of Emulsions for Parenteral Drug Delivery
An emulsion is a dispersion of two or more immiscible liquids stabilised by a surfactant or emulsifier coating the droplets and preventing coalescence by reducing interfacial tension or creating a physical repulsion between the droplets (1). Two common types of emulsions are found in parenteral drug delivery systems. Water in oil emulsions (W/O) are used in sustained release of steroids and vaccines by intramuscular injection. Oil in water (O/W) or lipid emulsions can be administered by a variety of parenteral routes (for example subcutaneous, intramuscular, intra-arterial), but are predominantly injected intravenously in parenteral nutrition applications.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
By Jack Stevens, Associate Foundation Scientist, Pam Mims, Director of Product Support and Services and Neil Coles, Marketing and Business Development Liaison at Fresenius Kabi Clayton Inc
Jack Stevens is the Associate Formulation Scientist at Fresenius Kabi Clayton NC, a contract pharmaceutical manufacturing and development company of sterile parenteral products such as injectable solutions, liposomes or emulsions. Jack received a BS in Chemistry from Kutztown University and a MS in Chemistry from Villanova University and has been with the company for four years.
Pamela Mims is the Director of Product Support and Services and has been with Fresenius Kabi for over fifteen years. Her group consists of research scientists performing formulation development, process scale-up, analytical method development, validation and stability studies. Pam received her BS in Animal Science and her MS in Nutrition from North Carolina State University.
Neil Coles serves as the Marketing and Business Development Liaison at Fresenius Kabi and has been with the company for nine years. He is responsible for maintaining client relationships in contract research and manufacturing alliances, and is the US representative for business development for Fresenius Product Partnering. Neil is a graduate of the State University of New York at Buffalo School of Pharmacy, with a BS in Medicinal Chemistry.
|
|
|
|
|
|
 |
News and Press Releases |
 |
Signant Health Senior Vice President Dr. David Daniel Honored in PharmaVOICE 100
Philadelphia, PA – August 1, 2019: Signant Health (formerly CRF Health
and Bracket) today announces that its Senior Vice President, Dr. David
Daniel, has been selected by PharmaVOICE as one of the top 100 most
inspiring people within the life sciences sector. Dr. Daniel was
selected from a large cross section of established professionals in the
life sciences industry for his passion to continually improve the way in
which science, technology and service interact. This honor swiftly
follows another recent mark of distinction for Dr. Daniel, having been
co-awarded the 2019 ISCDD Scientific Leadership Award.
More info >> |
|
 |
White Papers |
 |
|
Driving ROI: The Case for Investing in Contract & Site Regulatory Document Management Services
DrugDev
With tight timelines and complicated regulatory documentation requirements, getting a clinical trial up and running quickly is easier said than done. Key milestones can be achieved only after the successful negotiation of clinical trial agreements and completion of essential regulatory documents. Many clinical trials are hindered by inefficient, labor-intensive processes. Prolonged, inefficient activation can hamper investigator satisfaction and, ultimately, have a negative bottom-line impact for sponsors and CROs. In addition, the Sunshine Act is heightening the importance of financial disclosure in clinical trials. Without a robust financial disclosure strategy, sponsors cannot ensure that physician self-reported financial disclosure data are aligned with the payment data being reported through the Sunshine Act, increasing financial and regulatory risk.
More info >> |
|
 |
Industry Events |
 |
CPhI & P-MEC India
26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India
As
the pharma
industry looks increasingly towards India forhigh quality, low cost pharma solutions, CPhI & P-MEC Indiais the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer.
At
CPhI & P-MEC India, you will meet the movers and shakers from India’s
pharma machinery, technology and ingredients industries, giving you a
competitive advantage that will help grow your business.
More info >> |
|
|
